Skip to content
AZRAzora Therapeutics, Inc. (DE)

Earnings

When Azora Therapeutics, Inc. (DE) reports, what it reported each quarter, and how the stock took the results.

38 quarters. Jun 30, 2017 to Sep 30, 2026. mixed units.

Next results · Q4 2026Projected

10-K due Mar 1 – Apr 2

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 8 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 1 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$2.00M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$64.56MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$64.56M
    N/M
    EPS
    -$4.52
    N/M
    Effective October 29, 2026, the Company changed its name from Adial Pharmaceuticals, Inc. to Azora Therapeutics, Inc., and its common stock began trading on The Nasdaq Capital Market under the symbol ”AZR.”
  2. Q2 2026Aug 14, 2026, after the close
    Revenue
    —
    —
    Net income
    -$51.99M
    N/M
    EPS
    -$11.25
    N/M
  3. Q1 2026May 8, 2026, after the close
    Revenue
    —
    —
    Net income
    -$2.02M
    N/M
    EPS
    -$1.48
    N/M
  4. Q4 2025Mar 5, 2026, after the close
    Revenue
    —
    —
    Net income
    -$2.00M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 12, 202643 d10-Q——-$4.52—
Q2 2026Jun 30, 2026—Aug 14, 202645 d10-Q——-$11.25—
Q1 2026Mar 31, 2026—May 8, 202638 d10-Q——-$1.48—
FY 2025
Q4 2025derivedDec 31, 2025—Mar 5, 202664 d10-K————
Q3 2025Sep 30, 2025—Nov 13, 202544 d10-Q——-$2.02—
Q2 2025Jun 30, 2025—Aug 13, 202544 d10-Q——-$4.61—
Q1 2025Mar 31, 2025—May 14, 202544 d10-Q——-$8.52—
FY 2024
Q4 2024derivedDec 31, 2024Mar 4, 2025 · pre-marketMar 4, 202563 d10-K————
Q3 2024Sep 30, 2024—Nov 13, 202444 d10-Q——-$0.38—
Q2 2024Jun 30, 2024—Aug 13, 202444 d10-Q——-$0.59—
Q1 2024Mar 31, 2024—May 14, 202444 d10-Q——-$2.19—
Earlier years, FY 2017 to FY 2023

Source filings

10-QNov 12, 2026118910
10-QAug 14, 2026090051
10-QMay 8, 2026053907
10-KMar 5, 2026024175
10-QNov 13, 2025109979
10-QAug 13, 2025075695
10-QMay 14, 2025043281
10-KMar 4, 2025019771
10-QNov 13, 2024097519
10-QAug 13, 2024068262

Provenance

ProvenanceData status and checks

Azora Therapeutics, Inc. (DE) · CIK 1513525 · Engraved from SEC EDGAR